key: cord-0714405-dcctemht authors: Helgeson, Scott A.; Lim, Kaiser G.; Lee, Augustine S.; Niven, Alexander S.; Patel, Neal M. title: Aerosol Generation during Spirometry date: 2020-12-03 journal: Ann Am Thorac Soc DOI: 10.1513/annalsats.202005-569rl sha: b6921e5fc3e90204ed621813f5e400ac59a56a83 doc_id: 714405 cord_uid: dcctemht nan This was a single-center prospective study conducted at the Mayo Clinic in Florida. Five adult volunteer subjects without pulmonary disease consented to perform tidal breathing (VT), normal speaking, forced vital capacity (FVC), and maximum voluntary ventilation (MVV) maneuvers. The Mayo Clinic Institutional Review Board approved this study (20-005544). Particle measurement. A light-scattering particle counter (FLUKE 983) was used to simultaneously measure six channels of particle size distribution (0.3, 0.5, 1, 2, 5, and 10 mm), temperature, and humidity while each maneuver was being performed at each measured location. A minimum sampling volume of 1 L was obtained per measurement. Test conditions. To control for humidity, temperature, and other indeterminate ambient variables, room occupancy was limited to three persons (the subject and two investigators) during the study. The pulmonary function test room is 936 cubic feet and has 12.8 room air exchanges per hour. The ambient baseline measurement was obtained at the center of the room before and after each maneuver, with the subject and two investigators in the room and the door closed. The testing room was used only for this study on the day of the testing. The particle counter was positioned as follows: For the speaking portion, the particle counter was positioned 12 inches directly in front of the speaker. For the pulmonary function test portion, the air was sampled at the following three locations: 1) at a 90 8 angle to and touching the exhalation port (0 ft) on the pulmonary function equipment (Masterscreen PFT; Vyaire Medical), 2) at 1.5 ft from the exhalation port, halfway between where the patient and respiratory therapist sat, and 3) at 3 ft from the exhalation port. The number of particles counted and the volume of air sampled were recorded. The particle counter was zeroed before each test condition. Spirometry was performed outside the plethysmography box. A Microgard II filter (Vyaire Medical) was interposed between the mouthpiece and intake port for all maneuvers, as per manufacturer. For the speaking portion, each subject read "The Rainbow Passage" by Grant Fairbanks for 30 seconds. The subject then performed VT, FVC, and MVV through the pulmonary function test machine. If the subject coughed during the maneuver, the measurement was discarded, and the study was repeated once ambient particle count had returned to baseline. Each subject performed the test conditions twice. Analysis. A nonparametric distribution of measurements was assumed. The Mann-Whitney test for two group comparisons and Wilcoxon/Kruskal-Wallis test for multiple group comparisons was used. If the Kruskal-Wallis test was significant, a Steel test would be performed to compare each group to a single control. This was designated to be the ambient measurement obtained before the respective test. A P value of less than 0.05 was considered significant. The five subjects included four men (80%). The mean age was 37.6 6 8.4 years, the mean height was 177.6 6 3.9 cm, and the mean weight was 80.4 6 4.5 kg. Volunteers were white (60%), East Asian Indian (20%), and Asian (20%). Ambient room humidity was measured at 48%, and temperature was 23 8 C. Table 1 shows the increase in particle counts under different test conditions, with small respirable particles in the 0.3-mm range being generated the most. The FVC and MVV maneuvers generated increased small particles when compared with the ambient measurements with VT, FVC, and MVV. Proximity to the source was associated with significant increases in particle generation. With normal speaking, there was not an increase of generated 0.3-mm particles at 12 inches. When sampled close to the exhalation port position, all the maneuvers generated an increase in respirable 0.3-mm particles when compared with baseline ( Figure 1 ). Other aerosol-sized particles measured at 0.5 mm were also increased at this close position. At 1.5 ft and 3 ft from the exhalation port, there was no increase in particle generation for any of the trialed maneuvers. This report documents and characterizes aerosol particle generation from routine PFTs and supports precautions to mitigate the transmission of SARS-CoV-2. These precautions include the patient wearing a mask during the instructional phase, maintaining a distance of at least 1.5 ft between the subject and respiratory therapist, using disposable plastic covers over the PFT equipment, and using N95 and personal protective equipment for the respiratory therapist. This study provides valuable information guiding infectious control measures to ensure personnel and patient safety during pulmonary function testing. A limitation of this study was the small sample size of healthy volunteers, which increases the risk of multiple comparisons and decreases the overall stability of the results, but the results were consistent between volunteers, providing reassurance that larger sample sizes may provide similar results. In addition, the high room exchange and humidity may have contributed to particle dispersion and evaporation. Because the volunteers were healthy, the amount and size of particles generated could be considered the minimum, as a patient with nasal secretions or a productive cough may theoretically generate more particles. We did not assess the composition or infectivity of the measured particles, so the possibility of transmission is unknown but possible given the increase in particle generation. In conclusion, PFTs and normal breathing all generate aerosols rather than just droplets. The room air exchange, room turnaround time between testing, and distance between the patient and technician in the testing room are important. Particle generation close to the exhalation port warrants using a single-use plastic covering over the device, with the mouthpiece port and the exhalation port exposed, to avoid equipment contamination. The generation of aerosol-sized particles warrants the use of N95 masks and personal protective equipment during routine PFTs in patients who potentially have an airborne transmissible infectious disease. To the Editor: The Centers for Disease Control and Prevention attributes only 13% of incident tuberculosis (TB) disease in the United States to recent (<2 yr) transmission; nearly all of the remaining incident cases of TB disease are believed to occur via reactivation of latent TB infection (LTBI) acquired by individuals earlier in their lives (1) . It is estimated that up to 13 million people would test positive on the tuberculin skin test, and 9 (6-15) million people have untreated LTBI in the United States (2, 3). As such, treatment of LTBI is central to the current U.S. TB elimination strategy (4) . Treatment regimens such as 3 months of isoniazid and rifapentine (3HP), 4 months of rifampin (4R), and 6-9 months of isoniazid are efficacious in preventing TB disease (5-8), but effectiveness of any LTBI regimen in general populations may be limited by suboptimal levels of treatment initiation and completion (8, 9) and by discontinuation because of adverse effects (AEs) (7, 9) . Novel regimens with shorter duration of therapy, such as 6 weeks of daily 600-mg doses of rifapentine (6wP), which is currently being evaluated in a phase III clinical trial, may have important benefits, particularly if determined to be noninferior to 3HP and 9 months of isoniazid with lower discontinuation rates (10). HCA Lung Biological Network. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes Virological assessment of hospitalized patients with COVID-2019 SARS-CoV-2 viral load in upper respiratory specimens of infected patients Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals Visualizing speech-generated oral fluid droplets with laser light scattering Effect of voicing and articulation manner on aerosol particle emission during human speech The size and the duration of air-carriage of respiratory droplets and droplet-nuclei Author disclosures are available with the text of this letter at www.atsjournals.org.